Fournier's gangrene (FG) is a rapidly progressive, life-threatening necrotizing fasciitis of the perineal, genital, and perianal regions that requires emergent surgical debridement, broad-spectrum antibiotics, and aggressive resuscitation. [1-3] Mortality ranges from 7.5% to 50% depending on the series, with delays in diagnosis and treatment being the strongest modifiable risk factor. [1][4-5]
1. History
- Pain out of proportion to exam findings is a hallmark — intense perineal/scrotal/vulvar pain with initially minimal cutaneous changes [1]
- Characterize onset (abrupt vs. insidious), duration, and progression; FG can begin as a small abscess or skin break and escalate within hours [6-7]
- Ask about recent perianal/perineal procedures, urethral instrumentation, trauma, or surgery
- Inquire about urinary symptoms (dysuria, retention), bowel symptoms (constipation, diarrhea, rectal bleeding), and recent genital infections
- Assess for preceding perianal abscess, urinary tract infection, or skin wound as the infectious nidus — identified in ~64% of cases (perineal skin 24%, colorectal 21%, genitourinary 19%) [1]
- Screen for diabetes symptoms (polyuria, polydipsia), alcohol use, and immunosuppressive conditions
2. Alarm Features
- Crepitus (subcutaneous emphysema) — highly specific (94%) but present in only ~50% of cases [1]
- Skin necrosis, ecchymosis, or violaceous discoloration — late findings indicating advanced disease [1][3]
- Rapid extension of erythema beyond initial borders [3]
- Systemic toxicity: fever, tachycardia, hypotension, altered mental status
- Septic shock or multiorgan failure
- Extension to the abdominal wall or lower extremities — independently associated with increased mortality [8]
- Pain disproportionate to visible findings — the single most important early clue [2]
3. Medications
- SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin, ertugliflozin): FDA issued a safety warning in 2018 regarding FG risk, though large RCTs have not confirmed a statistically significant increased risk. If FG is suspected in a patient on an SGLT2 inhibitor, discontinue immediately. [9-12]
- Immunosuppressive agents (corticosteroids, chemotherapy, biologics) increase susceptibility
- Empiric antibiotic regimens (per IDSA guidelines): [6]
- Vancomycin or linezolid PLUS piperacillin-tazobactam (3.375 g IV q6-8h) — or a carbapenem (meropenem 1 g IV q8h), or ceftriaxone + metronidazole
- Add clindamycin (600–900 mg IV q8h) if toxic shock syndrome is suspected (limits exotoxin production) [3]
- Consider empirical antifungals in immunocompromised patients [3]
- Antibiotic de-escalation should be guided by intraoperative cultures [1]
4. Diet
- NPO status in the acute setting pending surgical debridement
- Aggressive IV fluid resuscitation is the priority
- Post-operatively, nutritional optimization is critical — high-protein diet to support wound healing
- Tight glycemic control in diabetic patients
- Alcohol cessation counseling if applicable
5. Review of Systems
- GU: dysuria, urethral discharge, scrotal/vulvar swelling, urinary retention
- GI: rectal pain, bleeding, constipation, diarrhea, fecal incontinence
- Constitutional: fevers, chills, rigors, malaise, weight loss
- Skin: rash, wound, recent abscess drainage
- Endocrine: symptoms of undiagnosed diabetes
- Psychiatric/Social: IV drug use, alcohol use, housing instability
6. Collateral History and Family History
- Confirm duration of symptoms from family/EMS — patients may underreport due to embarrassment regarding perineal complaints
- Assess functional baseline and prior hospitalizations
- Social context: homelessness, poor hygiene, limited access to care
- Family history is generally not contributory, though familial diabetes and immunodeficiency states are relevant risk factors
- Mental illness has been identified as an adverse prognostic factor [13]
7. Risk Factors
- Diabetes mellitus — present in 22%–65% of cases, the most common comorbidity [1][3][14]
- Obesity (17%–39%) [3]
- Chronic alcohol use (6%–30%) — independently associated with >2-fold increased odds of death [14]
- End-stage kidney disease — >3-fold increased odds of in-hospital death [14]
- Immunosuppression: HIV, leukemia, chemotherapy, chronic corticosteroids (4%–30%) [1][3]
- Peripheral arterial disease (3%–19%) [3]
- IV drug use (2%–80%) [3]
- Advanced age (≥65 years: ~5× mortality risk) [15]
- Up to 25% of patients have no identifiable comorbidities [3]
8. Differential Diagnosis
- Perianal/perineal abscess (without necrotizing component) — most common mimic; lacks systemic toxicity and crepitus
- Cellulitis/erysipelas — misdiagnosis rates for NSTI range from 41%–96% [3]
- Epididymo-orchitis — testicular tenderness with intact overlying skin; testes are typically spared in FG due to separate blood supply [1][6]
- Testicular torsion — acute scrotal pain without skin changes
- Incarcerated/strangulated inguinal hernia
- Pyoderma gangrenosum — non-infectious, associated with IBD
- Gas gangrene (clostridial myonecrosis) — deeper muscle involvement, distinct toxin-mediated features
- Allergic/contact dermatitis of the perineum
- Key distinguishing feature of FG: pain out of proportion to exam + systemic toxicity + rapid progression
9. Past Medical History
- Prior episodes of perineal abscess or FG (recurrence possible)
- Diabetes mellitus (check HbA1c — undiagnosed DM is common) [1]
- Chronic liver disease, cirrhosis
- Malignancy (especially colorectal, urologic)
- Prior perineal/anorectal surgery, urethral stricture disease
- Penile prosthesis or recent urologic instrumentation
- Inflammatory bowel disease
10. Physical Exam
- Vitals: fever, tachycardia, hypotension, tachypnea — signs of sepsis/SIRS
- Perineal inspection: erythema, edema, induration, skin necrosis, ecchymosis, bullae, purulent or foul-smelling discharge [1]
- Palpation: crepitus (subcutaneous gas), tenderness extending beyond visible erythema, "woody" induration of subcutaneous tissue
- Digital rectal exam (recommended by WSES guidelines) — assess sphincter tone, perianal abscess, rectal involvement [1]
- Genital exam: scrotal/vulvar swelling; testes are typically spared (non-perineal blood supply) [6]
- Assess extent of spread: mark borders of erythema with a skin marker and reassess q4-6h; extension beyond borders is highly concerning [3]
- Abdominal exam: assess for extension to anterior abdominal wall via Scarpa's fascia [1]
11. Lab Studies
- CBC: leukocytosis (WBC >15,400/μL suggestive of NSTI) [3]
- BMP: hyponatremia (<135 mmol/L), elevated creatinine, elevated BUN (>15 mg/dL) [3]
- Lactate: elevated in tissue ischemia and sepsis; independently associated with mortality [8]
- CRP, procalcitonin: inflammatory markers for severity assessment [1]
- Blood gas analysis: metabolic acidosis (low bicarbonate), low PCO₂ [1][16]
- Coagulation studies: DIC screen (PT/INR, fibrinogen, platelets) — coagulopathy is a strong predictor of mortality [17]
- Glucose, HbA1c, urine ketones: screen for undiagnosed diabetes (strongly recommended) [1]
- Blood cultures: obtain before antibiotics
- Albumin: low albumin associated with worse outcomes [16][18]
12. Imaging
- Imaging should NEVER delay surgical intervention (strong recommendation, WSES) [1]
- CT scan with IV contrast (first-line in stable patients): fascial thickening, soft tissue stranding, subcutaneous gas, fluid collections, abscess formation; helps determine extent and source of infection [1][19]
- Point-of-care ultrasound (POCUS): useful bedside tool when CT is not feasible; can demonstrate scrotal wall thickening, subcutaneous gas ("dirty shadowing"), paratesticular fluid, and preserved testicular blood flow on Doppler [1]
- Plain radiograph: may show subcutaneous gas but limited sensitivity
- MRI: superior soft tissue detail but impractical in the acute setting
- In hemodynamically unstable patients: forgo imaging and proceed directly to OR [1]
13. Special Tests
- LRINEC Score (Laboratory Risk Indicator for Necrotizing Fasciitis): uses CRP, WBC, hemoglobin, sodium, creatinine, glucose; score ≥6 has PPV 92% for necrotizing fasciitis, but poor sensitivity (43%–80%) — should not be used to rule out NSTI [1][3]
- FGSI (Fournier's Gangrene Severity Index): 9 parameters (temperature, HR, RR, Na, K, creatinine, Hct, WBC, bicarbonate); score ≥9 predicts 46% mortality vs. 4% mortality if <9 (AUROC 0.905) [1][8][20]
- qSOFA: rapid bedside tool (GCS, SBP, RR); high specificity (94.6%) for identifying low-risk patients [4]
- SOFA score: strong predictor of mortality (AUROC 0.830) [20]
- Intraoperative "finger test": lack of tissue resistance to blunt finger dissection along the fascial plane confirms necrotizing fasciitis
- Intraoperative cultures (aerobic, anaerobic, fungal): mandatory for targeted antibiotic therapy [1][3]
14. ECG
- ECG is indicated as part of the sepsis workup and preoperative assessment
- Assess for tachycardia, arrhythmias secondary to electrolyte derangements (hyperkalemia from AKI, metabolic acidosis)
- Evaluate for myocardial ischemia in the setting of septic shock, especially in patients with cardiovascular comorbidities
- No FG-specific ECG findings
15. Assessment
FG is a surgical emergency with a fulminant course driven by polymicrobial synergistic infection causing obliterative endarteritis, vessel thrombosis, tissue ischemia, and progressive fascial necrosis. [1] The infection is typically polymicrobial (Streptococcus, Staphylococcus, E. coli, Bacteroides, Enterococcus, Candida). [6][13] Key clinical pearl: early FG may mimic simple cellulitis — misdiagnosis rates are 41%–96%. [3] Severity stratification should use FGSI (prognosis) and LRINEC (diagnostic adjunct), but clinical suspicion must override negative scores. [1]
Complications include septic shock, multiorgan failure, DIC, extensive tissue loss requiring reconstructive surgery, sexual dysfunction, and death. [1][17]
16. Treatment Plan
Initial stabilization
- Aggressive IV fluid resuscitation; vasopressors if needed (sepsis protocol)
- Broad-spectrum IV antibiotics immediately upon suspicion: [1]
- Vancomycin (30 mg/kg/day in 2 divided doses) + piperacillin-tazobactam (3.375 g IV q6-8h) [6]
- OR vancomycin + meropenem (1 g IV q8h) [6]
- Add clindamycin (600–900 mg IV q8h) if toxic shock suspected [3]
- Consider antifungals (Candida species increasingly identified and associated with worse outcomes) [13]
Surgical management
- Emergent radical debridement of all necrotic tissue — the single most important determinant of outcome [3]
- Return to OR within 24 hours for re-evaluation; average 3 debridements per patient [21]
- Obtain deep tissue cultures (aerobic, anaerobic, fungal) intraoperatively [3]
- Orchiectomy only if strictly necessary (testes usually spared) [1]
- Fecal diversion: consider colostomy or fecal management system (e.g., Flexi-Seal) for sphincter involvement, fecal incontinence, or continued wound contamination; however, colostomy has not been shown to reduce mortality and carries its own morbidity — non-invasive methods should be tried first [1][22-23]
- Suprapubic cystostomy if urethral disruption or extensive penile debridement [1]
Adjunctive therapies
- Negative pressure wound therapy (NPWT/VAC): promotes granulation tissue, removes exudate; best initiated after wound is deemed stable following serial debridements [1][3]
- Hyperbaric oxygen therapy (HBOT): meta-analyses suggest lower mortality, but evidence is limited to observational studies; IDSA recommends against, other guidelines suggest considering it; should never delay surgery [3]
- Nutritional support, glycemic control, wound care
17. Disposition
- All patients require admission — there is no outpatient management for FG
- ICU admission for hemodynamic instability, sepsis, multiorgan dysfunction, or need for vasopressors
- Surgical floor for stable patients post-debridement requiring serial wound care
- Consider transfer to a high-volume center or burn center for complex cases — but initial debridement should occur at the presenting hospital before transfer, as transferred patients have up to double the mortality rate if debridement is delayed [3]
- Multidisciplinary team: general/emergency surgery, urology, colorectal surgery, plastic surgery, infectious disease, critical care [1]
18. Follow Up / Return Precautions
- Inpatient: serial wound checks q4-6h in the early postoperative period; plan for return to OR within 24 hours and then as needed until wound is clean [3][21]
- Post-discharge: close surgical follow-up for wound management; average time to complete wound healing is ~4.8 months [24]
- Reconstructive surgery (skin grafts, flaps) may be needed for large defects [25]
- Stoma reversal planning if colostomy was performed (carries its own complication risk) [24]
- Return precautions: worsening pain, new swelling/redness, fever, foul-smelling drainage, wound breakdown
- Screen for and manage psychological sequelae (body image, sexual dysfunction, PTSD)
- Long-term diabetes management optimization
- Counsel on modifiable risk factors (alcohol cessation, glycemic control, hygiene)
References
1. Anorectal Emergencies: WSES-AAST Guidelines. — Tarasconi A, Perrone G, Davies J, et al. World Journal of Emergency Surgery : WJES. 2021.
2. Fournier Gangrene: A Review for Emergency Clinicians. — Montrief T, Long B, Koyfman A, Auerbach J. The Journal of Emergency Medicine. 2019.
3. Necrotizing Soft Tissue Infections: A Review. — McDermott J, Kao LS, Keeley JA, et al. JAMA Surgery. 2024.
4. Quick Sequential Organ Failure Assessment and Fournier Gangrene Severity Index as Predictors for Mortality in Fournier Gangrene Patients: A Retrospective Cohort Study of 153 Patients. — Bestari MG, Adi K, Mustafa A. The American Journal of Emergency Medicine. 2025.
5. Higher Morbidity and Mortality in Females With Fournier Gangrene Compared With Males: Insights From National Inpatient Sample Data. — Abbasi B, Hacker E, Ghaffar U, et al. The Journal of Urology. 2025.
6. Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by the Infectious Diseases Society of America. — Stevens DL, Bisno AL, Chambers HF, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2014.
7. Necrotizing Soft-Tissue Infections. — Stevens DL, Bryant AE. The New England Journal of Medicine. 2017.
8. Validation of the Fournier's Gangrene Severity Index in a Large Contemporary Series. — Corcoran AT, Smaldone MC, Gibbons EP, Walsh TJ, Davies BJ. The Journal of Urology. 2008.
9. Fournier Gangrene Associated With Sodium-Glucose Cotransporter-2 Inhibitors: A Review of Spontaneous Postmarketing Cases. — Bersoff-Matcha SJ, Chamberlain C, Cao C, Kortepeter C, Chong WH. Annals of Internal Medicine. 2019.
10. Genitourinary Tract Infections in Patients Taking SGLT2 Inhibitors: JACC Review Topic of the Week. — Kittipibul V, Cox ZL, Chesdachai S, et al. Journal of the American College of Cardiology. 2024.
11. SGLT2 Inhibitors and GLP-1 Receptor Agonists: Established and Emerging Indications. — Brown E, Heerspink HJL, Cuthbertson DJ, Wilding JPH. Lancet. 2021.
12. Case Literature Analysis of Fournier's Gangrene Caused by Sodium-Glucose Protein-2 Inhibitors. — Liu H. Frontiers in Medicine. 2023.
13. Factors Associated With Fournier's Gangrene Survival in a Diverse Urban Community: A 15-Year Review. — Matloubieh JE, Patel RD, Fram E, Lowe FC. BJU International. 2025.
14. Adult Male Fournier Gangrene Hospitalizations With and Without End-Stage Kidney Disease: A 5-Year Nationwide Analysis. — Manadan J, Whittier W. Clinical Nephrology. 2026.
15. Temperature-Neutrophils-Multiple Organ Failure Grading as a Prognostic Indicator in Fournier Gangrene. — Tazeoglu D, Benli S, Colak T. Surgical Infections. 2023.
16. Enhanced Prognostic Model for Mortality in Patients With Fournier Gangrene: Validation of the Fournier Gangrene Mortality Index and Integration of Platelet Count and PCO₂. — Altunok İ, Özdemir S. E The American Journal of Emergency Medicine. 2025.
17. Prognostic Factors and Clinical Outcomes in Fournier's Gangrene: A Retrospective Study of 35 Patients. — Hong HB, Lee JW, Park CH. BMC Infectious Diseases. 2024.
18. CALLY Index as a Prognostic Marker for 30-Day Mortality in Fournier Gangrene: A Multicenter Retrospective Cohort Study. — Canlikarakaya F, Ceylan C, Doğan İ, et al. C The American Surgeon. 2026.
19. Fournier Gangrene: Pictorial Review. — Wongwaisayawan S, Krishna S, Haroon M, Nisha Y, Sheikh A. Abdominal Radiology. 2020.
20. Comparison of Different Scoring Systems for Predicting in-Hospital Mortality for Patients With Fournier Gangrene. — Azmi YA, Alkaff FF, Renaldo J, et al. World Journal of Urology. 2023.
21. Interventions for Necrotizing Soft Tissue Infections in Adults. — Hua C, Bosc R, Sbidian E, et al. The Cochrane Database of Systematic Reviews. 2018.
22. Fournier's Gangrene and Fecal Diversion. When, in Which Patients, and What Type Should I Perform?. — Ortega Ferrete A, López E, Juez Sáez LD, et al. Langenbeck's Archives of Surgery. 2023.
23. Relationship Between Diversional Stoma and Mortality Rate in Fournier's Gangrene: A Systematic Review and Meta-Analysis. — Sarofim M, Di Re A, Descallar J, Toh JWT. Langenbeck's Archives of Surgery. 2021.
24. Long-Term Follow-Up of Fournier's Gangrene in a Tertiary Care Center. — Rosen DR, Brown ME, Cologne KG, Ault GT, Strumwasser AM. The Journal of Surgical Research. 2016.
25. Role of Diverting Colostomy and Reconstruction in Managing Fournier's Gangrene-a Narrative Review. — Huang S, Chen DC, Perera M, Lawrentschuk N. BJU International. 2024.